AKESO(HK:09926) Sou Hu Cai Jing·2025-04-24 02:18Group 1: Market Performance - The Hang Seng Biotechnology Index (HSHKBIO) rose by 2.65% as of April 24, 2025, with notable increases in constituent stocks such as Rongchang Biopharmaceutical (09995) up 11.47%, Ascentage Pharma-B (06855) up 8.46%, and Innovent Biologics (01801) up 7.68% [1] - The Hang Seng Biotechnology ETF (513280) also increased by 2.62%, marking its fifth consecutive rise, with the latest price at 0.9 HKD [1] - Over the past week, the Hang Seng Biotechnology ETF has accumulated an 8.79% increase, ranking in the top third among comparable funds [1] - The ETF's liquidity was strong, with a turnover rate of 13.76% and a trading volume of 36.43 million HKD, indicating active market participation [1] - In the past month, the ETF's average daily trading volume was 82.80 million HKD, and it saw a significant increase of 7 million shares in the last month, placing it in the top third of comparable funds [1] Group 2: Company Developments - On April 23, 2025, CanSino Biologics announced that its bispecific antibody drug, Ivorisumab, successfully outperformed PD-1 in a head-to-head trial against BeiGene's Tislelizumab for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) [4] - The trial results were described as having strong positive outcomes, with statistical significance and major clinical benefits, leading to a surge in CanSino's stock price, which rose over 10% to reach a historical high of 100 HKD per share [4] - The National Medical Products Administration (NMPA) has proposed a six-year data protection period for innovative drug trial data, which is seen as a significant encouragement for drug research and development [4] Group 3: Industry Insights - Guosen Securities highlighted the importance of focusing on innovative drugs that are accelerating their international presence and benefiting from policy support [5] - Since the beginning of 2025, domestic innovative drug companies have completed numerous outbound licensing transactions, indicating a growing global competitive edge in research and clinical data [5] - The upstream pharmaceutical research and development sector is viewed as a critical component of China's self-sufficient industrial chain, with opportunities for quality companies to accelerate growth amid tariff impacts from the U.S. [5] Group 4: ETF Characteristics - The Hang Seng Biotechnology ETF (513280) is noted for having the lowest fees in the market for Hong Kong innovative drug products, with a management fee of only 0.15% per year and a custody fee of 0.05% per year, significantly lower than similar products [6] - As of December 2024, the ETF's index composition includes 66.4% innovative drugs, 15.4% CXO, and over 9% in pharmaceutical distribution and medical devices, indicating a balanced exposure across sectors [6]